Physician profile
William Mc Comb
NPI 1043235047
$3,567.46
in general payments reported to CMS, 2019-2025
33 companies · $810 in 2025
The $810 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $216 · 2021: $182 · 2022: $166 · 2023: $659 · 2024: $1,341 · 2025: $810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,809.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $544.14 | 2022-2025 | Pico 7, Collagenase Santyl, Renasys Go V2 Home |
| Kerecis Limited | $461.46 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Abbvie INC. | $429.25 | 2019-2025 | |
| Urgo Medical North America, LLC | $310.63 | 2023-2025 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap, Urgok2, Drawtex Hydroconductive Wound Dressing With Levafiber 4x4 |
| Mimedx Group, INC. | $238.10 | 2024-2025 | |
| Paratek Pharmaceuticals, INC. | $223.33 | 2024-2025 | Nuzyra |
| Convatec INC. | $212.42 | 2019-2025 | |
| Organogenesis INC. | $120.53 | 2023-2025 | Affinity, Puraply, Apligraf |
| Nestle Healthcare Nutrition INC. | $117.33 | 2021-2022 | |
| Integra Lifesciences Corporation | $108.51 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Reapplix INC. | $102.37 | 2024-2025 | 3c Patch Kit - Box |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.34 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $72.86 | 2019-2021 | |
| Solventum Corporation | $54.48 | 2024-2025 | Activ.A.C., Promogran Prisma, 3m Coban |
| Janssen Pharmaceuticals, INC | $52.90 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Reprise Biomedical, INC. | $51.37 | 2024-2025 | Miro3d |
| Daiichi Sankyo INC. | $48.79 | 2020-2022 | |
| Ironwood Pharmaceuticals, INC | $31.73 | 2020-2021 | |
| Novo Nordisk INC | $31.13 | 2021 | |
| Melinta Therapeutics, LLC | $28.64 | 2019 | |
| Kci USA, INC. | $27.80 | 2022-2023 | Activ.A.C. Ion Progress, Promogran Prisma, V.A.C. Dermatac |
| Ethicon US, LLC | $27.35 | 2019 | |
| Amgen INC. | $21.58 | 2021 | |
| Amarin Pharma, INC. | $18.94 | 2020 | |
| Allergan, INC. | $18.36 | 2020 | |
| Averitas Pharma INC. | $18.11 | 2024 | Qutenza |
| Hartmann USA, INC. | $16.38 | 2024 | Zetuvit Plus 10x10 P10 |
| La Jolla Pharmaceutical Company | $14.99 | 2023 | Xerava |
| Aroa Biosurgery Incorporated | $13.26 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.54 | 2020 | |
| Merck Sharp & Dohme LLC | $12.46 | 2019 | |
| Intercept Pharmaceuticals, INC. | $12.44 | 2020 | |
| Bsn Medical INC | $11.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mc Comb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.